GeoVax Labs (GOVX, Financial) has encountered a significant hurdle following the abrupt cessation of its Phase 2b clinical trial for the GEO-CM04S1 COVID-19 vaccine. This trial, funded by the Biomedical Advanced Research and Development Authority (BARDA), was intended to assess the vaccine's efficacy compared to an approved mRNA vaccine, involving 10,000 participants under the Project NextGen banner.
The decision to terminate the trial for governmental convenience has prompted D. Boral Capital to lower the price target for GeoVax from $18 to $14, although the firm maintains a Buy rating on the stock. This development raises questions about the future of GeoVax’s vaccine initiatives and the financial implications following the removal of all anticipated BARDA revenues and stockpile awards from the firm’s financial model.
The halted trial represents a considerable setback for GeoVax as it navigates the next steps in its vaccine development strategy amidst these new challenges.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Geovax Labs Inc (GOVX, Financial) is $14.60 with a high estimate of $20.00 and a low estimate of $8.00. The average target implies an upside of 1,812.75% from the current price of $0.76. More detailed estimate data can be found on the Geovax Labs Inc (GOVX) Forecast page.
Based on the consensus recommendation from 5 brokerage firms, Geovax Labs Inc's (GOVX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
